By Counterforce Health Team in Kesimpta (ofatumumab) —

How to Get Kesimpta (ofatumumab) Covered by Humana in North Carolina: Complete Prior Authorization and Appeal Guide

Quick Answer: Getting Kesimpta Approved by Humana in North Carolina

Kesimpta (ofatumumab) requires prior authorization from Humana Medicare Advantage plans in North Carolina, typically at Tier 5 specialty coverage. Your fastest path to approval: Have your neurologist submit a PA request with documentation of relapsing MS diagnosis, hepatitis B screening, and either step therapy failure with preferred DMTs or high disease activity. If denied, you have 65 days to appeal internally, then can request a free external review through North Carolina's Smart NC program within 120 days.

First step today: Call Humana member services (number on your ID card) to confirm Kesimpta's formulary status and PA requirements for your specific plan.

Table of Contents

When Alternatives Make Sense

Before pursuing a lengthy prior authorization battle for Kesimpta, it's worth understanding when Humana's formulary alternatives might be clinically appropriate. According to Humana's Medicare formulary guidelines, most plans require step therapy through preferred disease-modifying therapies (DMTs) before approving specialty injectables like Kesimpta.

Consider alternatives if you have:

  • Newly diagnosed relapsing MS without prior treatment failures
  • Mild disease activity without aggressive features
  • Concerns about injection site reactions or infection risks
  • Cost sensitivity (Tier 5 specialty drugs have the highest copays)

Stick with Kesimpta if you have:

  • Failed or can't tolerate multiple oral DMTs
  • High disease activity (frequent relapses, new MRI lesions)
  • Preference for monthly self-injection over infusions
  • Previous success with anti-CD20 therapies

Typical Formulary Alternatives

Based on Humana's 2024 Medicare formulary data, common MS DMT alternatives include:

Tier 1-2 Options (Lower Cost)

  • Glatiramer acetate (generic Copaxone) - Daily injection
  • Interferon beta-1a generics - Weekly injection
  • Dimethyl fumarate (generic Tecfidera) - Twice daily oral

Tier 3-4 Options (Moderate Cost)

  • Fingolimod (generic Gilenya) - Daily oral
  • Teriflunomide (Aubagio) - Daily oral
  • Natalizumab (Tysabri) - Monthly infusion

Other Anti-CD20 Options

  • Ocrelizumab (Ocrevus) - Every 6 months infusion
  • Rituximab (off-label) - Variable dosing
Note: Formulary placement varies by specific Humana plan. Check your plan's prescription drug guide for current tier status.

Pros and Cons Overview

Alternative Access Considerations Testing Requirements Monitoring
Glatiramer acetate Usually no PA required Basic labs Injection site checks
Interferon beta May require PA Liver function, CBC Depression screening
Dimethyl fumarate Often preferred tier Lymphocyte count Quarterly CBC
Fingolimod PA for cardiac history EKG, ophthalmology First-dose monitoring
Ocrelizumab PA required Hepatitis B, immunoglobulins Infection surveillance

Access advantages of alternatives:

  • Lower tier placement reduces copays
  • Established safety profiles
  • Some available as generics
  • Less restrictive PA criteria

Potential disadvantages:

  • May be less effective for aggressive MS
  • Different side effect profiles
  • Some require more frequent dosing
  • Infusion-based options need clinic visits

Exception Strategy

When formulary alternatives aren't clinically appropriate, you can request coverage exceptions. Humana's Medicare exception process allows three types of requests:

Formulary Exception

Request coverage for a non-formulary drug when alternatives are ineffective or contraindicated.

Required documentation:

  • Prescriber statement explaining why formulary alternatives won't work
  • Medical records showing contraindications or failures
  • Clinical rationale for Kesimpta specifically

Tiering Exception

Request lower copay tier placement when preferred alternatives aren't suitable.

Step Therapy Waiver

Skip required trial of preferred drugs when medically inappropriate.

Evidence that strengthens exceptions:

  • Documented allergies or contraindications to preferred drugs
  • Previous treatment failures with clear documentation
  • Rapid disease progression requiring immediate intervention
  • Specialist recommendation with clinical justification
Tip: Exception requests are most successful when they demonstrate that formulary alternatives pose specific medical risks or have already failed for your individual case.

Switching Logistics

If you decide to try a formulary alternative first, coordinate carefully with your care team:

Provider Coordination

  1. Schedule MS specialist visit to discuss alternative options
  2. Review medication history including previous DMT trials
  3. Plan monitoring schedule for new medication
  4. Establish failure criteria for documenting if alternative doesn't work

Pharmacy Coordination

  • Verify new medication's formulary status
  • Confirm specialty pharmacy requirements if needed
  • Understand copay responsibilities
  • Set up automatic refills if appropriate

Documentation During Trial

Keep detailed records of:

  • Treatment start date and dosing
  • Any side effects or tolerability issues
  • Disease activity (new symptoms, relapses)
  • MRI changes if scans are performed
  • Functional status changes

This documentation becomes crucial if you later need to demonstrate treatment failure for a Kesimpta exception.

Re-trying for Kesimpta Later

If you start with an alternative DMT, you can still pursue Kesimpta coverage later with stronger evidence:

Strengthen your case by documenting:

  • Specific dates and outcomes of alternative therapy trials
  • Breakthrough disease activity despite treatment
  • Side effects that limit adherence or quality of life
  • Specialist recommendations for therapy escalation

Timing considerations:

  • Most plans require 3-6 months trial of alternatives
  • Document any relapses or MRI progression during trial period
  • Annual plan formulary changes may affect coverage

Re-submission strategy:

  • Submit new PA with updated clinical history
  • Include comparative effectiveness arguments
  • Emphasize individual medical necessity factors

Step-by-Step: Fastest Path to Approval

1. Verify Coverage Requirements (Patient)

What to do: Call Humana member services and ask about Kesimpta's formulary status, PA requirements, and preferred alternatives. Timeline: Same day Source: Humana member portal

2. Gather Clinical Documentation (Clinic)

Required documents:

  • Recent MRI reports (within 6-12 months)
  • Hepatitis B screening results (HBsAg, anti-HBc)
  • Vaccination records (complete 2-4 weeks before starting)
  • Documentation of prior DMT failures or contraindications Timeline: 1-2 weeks Source: Kesimpta prescribing information

3. Submit Prior Authorization (Provider)

How to submit: Humana provider portal or fax to 877-486-2621 Include: ICD-10 code G35, clinical rationale, supporting documentation Timeline: Standard 15-30 days, expedited ≤72 hours if urgent Source: CarelonRx PA criteria

4. Follow Up on Decision (Patient/Provider)

Check status: Humana provider portal or member services If approved: Coordinate specialty pharmacy delivery If denied: Review denial reason and prepare appeal

Appeals Playbook for Humana in North Carolina

Internal Appeal (First Level)

  • Deadline: 65 days from denial notice
  • Submit via: Humana appeals form or same contacts as original PA
  • Timeline: 7 calendar days for decision
  • Include: Additional clinical evidence, peer-reviewed literature, specialist letter

External Review (North Carolina Smart NC)

  • When to use: After exhausting internal appeals
  • Deadline: 120 days from final internal denial
  • How to apply: Smart NC external review request
  • Cost: Free to patients
  • Timeline: 45 days standard, 3 days expedited
  • Success factors: Independent medical review, not insurance company decision
Note: For urgent situations where delays could seriously harm your health, request expedited external review with prescriber certification.

Smart NC Contact Information

  • Phone: 1-855-408-1212 (free advocacy support)
  • Website: NC Department of Insurance
  • Services: Form completion help, medical record gathering, insurer communication

Common Denial Reasons & Fixes

Denial Reason How to Overturn
No relapsing MS diagnosis Submit recent MRI, neurologist letter confirming CIS/RRMS/active SPMS with ICD-10 G35
Missing hepatitis B screening Complete HBsAg and anti-HBc testing, submit results with resubmission
Step therapy required Document failures/contraindications to preferred DMTs with dates and clinical outcomes
Quantity limits exceeded Request override for loading dose (3 injections first month) with clinical justification
Not medically necessary Provide specialist letter explaining why Kesimpta specifically is required for patient's condition

FAQ

How long does Humana PA take in North Carolina? Standard PA decisions take 15-30 days, but you can request expedited review (≤72 hours) if delays would harm your health. Source: Humana PA guidelines

What if Kesimpta is non-formulary on my plan? You can request a formulary exception with prescriber support showing why covered alternatives won't work. Include clinical documentation of contraindications or previous failures.

Can I request an expedited appeal? Yes, if your treating physician certifies that standard timing would seriously jeopardize your health. Both Humana internal appeals and NC Smart NC external reviews offer expedited options.

Does step therapy apply if I failed DMTs outside North Carolina? Yes, document previous treatment failures regardless of where they occurred. Include medical records, dates of treatment, and specific reasons for discontinuation.

How much will Kesimpta cost with Humana coverage? As a Tier 5 specialty drug, expect significant copays. Check your plan's formulary for exact amounts and explore manufacturer copay assistance if eligible.

Counterforce Health helps patients and providers navigate complex prior authorization and appeals processes for specialty medications. Our platform analyzes denial letters and plan policies to create targeted, evidence-backed appeals that align with payer requirements. By turning insurance denials into strategic opportunities, we help ensure patients get access to the medications they need. Learn more at CounterforceHealth.org.

When facing insurance coverage challenges for specialty medications like Kesimpta, having the right documentation and understanding payer-specific requirements makes all the difference. Counterforce Health's platform specializes in identifying denial reasons and crafting point-by-point rebuttals that address plan policies directly, helping patients and providers build stronger cases for medication approval.

Sources & Further Reading

Disclaimer: This information is for educational purposes only and does not constitute medical advice. Coverage policies vary by plan and change over time. Always verify current requirements with your insurance plan and consult your healthcare provider for medical decisions. For official North Carolina insurance assistance, contact Smart NC at 1-855-408-1212.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.